Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
Nair
M P
MP
Hamad Al-Essa Organ Transplant Centre, Kuwait, Kuwait.
Nampoory
M R
MR
Johny
K V
KV
Costandi
J N
JN
Abdulhalim
M
M
El-Reshaid
W
W
Al-Muzairai
I
I
Ninan
V T
VT
Samhan
M
M
Al-Mousawi
M
M
D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D015897:Comorbidity; D000077561:Daclizumab; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D006973:Hypertension / Q000150:complications; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000150:complications; D011993:Recombinant Fusion Proteins; D012449:Safety; D013997:Time Factors; D014184:Transplantation, Homologous
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D000077561:Daclizumab